CN110167593A - 用于治疗或预防干扰素-γ相关适应症的方法、组合物和给药方案 - Google Patents

用于治疗或预防干扰素-γ相关适应症的方法、组合物和给药方案 Download PDF

Info

Publication number
CN110167593A
CN110167593A CN201780080221.6A CN201780080221A CN110167593A CN 110167593 A CN110167593 A CN 110167593A CN 201780080221 A CN201780080221 A CN 201780080221A CN 110167593 A CN110167593 A CN 110167593A
Authority
CN
China
Prior art keywords
acid sequence
seq
amino acid
antibody
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780080221.6A
Other languages
English (en)
Chinese (zh)
Inventor
C.德敏
W.费尔林
F.德贝内德蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AG
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Publication of CN110167593A publication Critical patent/CN110167593A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780080221.6A 2016-10-24 2017-10-24 用于治疗或预防干扰素-γ相关适应症的方法、组合物和给药方案 Pending CN110167593A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
US62/411783 2016-10-24
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Publications (1)

Publication Number Publication Date
CN110167593A true CN110167593A (zh) 2019-08-23

Family

ID=60957345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080221.6A Pending CN110167593A (zh) 2016-10-24 2017-10-24 用于治疗或预防干扰素-γ相关适应症的方法、组合物和给药方案

Country Status (12)

Country Link
EP (1) EP3528845A2 (https=)
JP (3) JP2019532970A (https=)
KR (2) KR20240148970A (https=)
CN (1) CN110167593A (https=)
AU (2) AU2017352033A1 (https=)
BR (1) BR112019008156A2 (https=)
CA (2) CA3244670A1 (https=)
EA (1) EA201990930A1 (https=)
IL (1) IL266174B2 (https=)
MX (2) MX2019004766A (https=)
SG (1) SG11201903659WA (https=)
WO (1) WO2018078442A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884459A (zh) * 2016-04-26 2018-11-23 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121588213A (zh) 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP2023521519A (ja) * 2020-04-06 2023-05-24 セレディット エルエルシー キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151277A (zh) * 2005-01-27 2008-03-26 诺维莫尼公司 抗干扰素γ抗体及其使用方法
CN104159919A (zh) * 2011-11-23 2014-11-19 安姆根有限公司 使用抗干扰素γ抗体的治疗方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
JPWO2015190378A1 (ja) 2014-06-10 2017-04-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定なアダリムマブ水性製剤
CN121588213A (zh) * 2015-05-07 2026-03-03 瑞典孤儿比奥维特鲁姆股份公司 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151277A (zh) * 2005-01-27 2008-03-26 诺维莫尼公司 抗干扰素γ抗体及其使用方法
CN104159919A (zh) * 2011-11-23 2014-11-19 安姆根有限公司 使用抗干扰素γ抗体的治疗方法

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
C BRACAGLIA等: "Anti interferon-gamma (IFNg) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis", 《PEDIATRIC RHEUMATOLOGY》, vol. 13, no. 1, 28 September 2015 (2015-09-28), pages 1 - 2 *
C BRACAGLIA等: "Anti interferon-gamma (IFNg) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis", 《PEDIATRIC RHEUMATOLOGY》, vol. 13, pages 1 - 2 *
CLINICALTRIALS: "NCT01818492", 《CLINICALTRIALS》 *
CLINICALTRIALS: "NCT01818492", 《CLINICALTRIALS》, 14 July 2016 (2016-07-14) *
CRISTINA DE MIN等: "Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma(IFNg)Antibody, in Patients with Hemophagocytic Lymphohistiocytosis(HLH)", 《ACR MEETING ABSTRACTS》, 29 September 2015 (2015-09-29), pages 1 - 2 *
CRISTINA DE MIN等: "Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma(IFNg)Antibody, in Patients with Hemophagocytic Lymphohistiocytosis(HLH)", 《ACR MEETING ABSTRACTS》, pages 226 - 227 *
EMA/COMP: "Public summary of opinion on orphan designation Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis", 《EMA/COMP》 *
EMA/COMP: "Public summary of opinion on orphan designation Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis", 《EMA/COMP》, 10 June 2010 (2010-06-10) *
M. B. JORDAN 等: "How I treat hemophagocytic lymphohistiocytosis", 《BLOOD》 *
M. B. JORDAN 等: "How I treat hemophagocytic lymphohistiocytosis", 《BLOOD》, 13 October 2011 (2011-10-13) *
SUMIT GOSWAMI等: "Developments and Challenges for mAb-Based Therapeutics", 《ANTIBODIES》, vol. 2, no. 3, pages 452 - 500, XP055128980, DOI: 10.3390/antib2030452 *
SUMIT GOSWAMI等: "Developments and Challenges for mAb-Based Therapeutics:Developments and Challenges for mAb-Based Therapeutics", 《ANTIBODIES》, vol. 2, no. 3, 16 August 2013 (2013-08-16), pages 452 - 500, XP055128980, DOI: 10.3390/antib2030452 *
USMANI GN等: "Advances in understanding the pathogenesis of HLH", 《BRITISH JOURNAL OF HAEMATOLOGY》, vol. 161, no. 5, pages 609 - 622, XP071120958, DOI: 10.1111/bjh.12293 *
USMANI GN等: "Advances in understanding the pathogenesis of HLH:Advances in understanding the pathogenesis of HLH", 《BRITISH JOURNAL OF HAEMATOLOGY》, vol. 161, no. 5, 12 April 2013 (2013-04-12), pages 609 - 622, XP071120958, DOI: 10.1111/bjh.12293 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884459A (zh) * 2016-04-26 2018-11-23 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
CN108884459B (zh) * 2016-04-26 2024-04-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法

Also Published As

Publication number Publication date
KR20240148970A (ko) 2024-10-11
MX2025012950A (es) 2025-12-01
CA3244670A1 (en) 2025-11-29
JP2022187025A (ja) 2022-12-15
JP2019532970A (ja) 2019-11-14
AU2017352033A1 (en) 2019-06-06
MX2019004766A (es) 2019-09-27
WO2018078442A3 (en) 2018-08-23
IL266174A (en) 2019-06-30
CA3041434A1 (en) 2018-05-03
AU2024264563A1 (en) 2024-11-28
JP7562074B2 (ja) 2024-10-07
WO2018078442A2 (en) 2018-05-03
EA201990930A1 (ru) 2019-11-29
BR112019008156A2 (pt) 2019-07-02
EP3528845A2 (en) 2019-08-28
IL266174B1 (en) 2024-06-01
KR20190071785A (ko) 2019-06-24
IL266174B2 (en) 2024-10-01
JP2024170569A (ja) 2024-12-10
SG11201903659WA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US12275785B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US12195530B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP7562074B2 (ja) インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
EP3877051A1 (en) Treatment for giant cell arteritis
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
EA049189B1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240821

Address after: Basel, SUI

Applicant after: Swedish orphan biovitrum AG

Country or region after: Switzerland

Address before: Geneva, Switzerland

Applicant before: NOVIMMUNE S.A.

Country or region before: Switzerland

TA01 Transfer of patent application right